MedPath

EmbracePlus, Care App and Aura Usability Study

Completed
Conditions
Usability
Interventions
Other: Usability Assessment
Registration Number
NCT04807608
Lead Sponsor
Empatica, Inc.
Brief Summary

The purpose of this study is to evaluate the usability of the system which includes the wearable device, app and cloud data processing, including an algorithm (Aura) capable of detecting possible early signs of respiratory infections in healthy individuals.

In addition, the investigators would like to evaluate the presence of any allergic reactions to materials used in the manufacture of the EmbracePlus.

Detailed Description

The investigators wish to evaluate of the usability, according to the requirements of IEC 62366-1:2015/AMD 1:2020 of a wearable device - EmbracePlus, the Empatica Care app and Aura algorithm, an early-warning wearable/AI platform for alerting to COVID-19 and other possible respiratory infections before a person is symptomatic. The system consists is a smartwatch coupled with an AI algorithm (Aura) developed by Empatica. The Aura algorithm analyzes physiological signals and derived biomarkers (such as sleep patterns) in order to detect possible early signs of respiratory infection. It has been originally developed by Empatica, validated with influenza and rhinovirus data and is being currently validated for COVID-19 infections.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
335
Inclusion Criteria
  1. Age: Participants must be between the ages of 18-99
  2. Gender: No restrictions
  3. Disease: healthy participants
  4. Adult participant must either be able to give consent
  5. Participants must be fluent in the language of the consent forms (Currently limited to English).
  6. Participants must reside in the United States.
  7. Participants should have a physical home address where they can receive the device
  8. Participants must have a personal smartphone Apple or Android (at least iPhone 8 or Android 5.0)
Exclusion Criteria
  1. Participants must not have broken or injured skin at the wrist where EmbracePlus is worn, and they must be able to tolerate wearing EmbracePlus snugly for long periods of time. Thus, they should not have allergies to the material composition of the EmbracePlus smartwatch, or discomfort wearing a smartwatch during the night.
  2. Participants are not willing to wear the device during nighttime
  3. Participants should not have pre-existing cardiovascular disease or respiratory disease
  4. Participants must not be pregnant or planning to become pregnant within two months at the time of screening

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Healthy UsersUsability AssessmentEach subject will be provided with a wearable device (smartwatch EmbracePlus manufactured by Empatica), to be worn every day outside of work hours for a total of 6 weeks. After the 6 weeks of data collection the participant will be asked to fill an online questionnaire related to the system usability (max 20 min).
Primary Outcome Measures
NameTimeMethod
EmbracePlus, Care App and Aura Usability: Based on user surveyAfter 6 weeks of system usage

Determine the ease of use of the system composed of EmbracePlus, Care app and Aura algorithm and user satisfaction, by means of a survey items that include both Likert-scale items that will be analyzed quantitatively and open-ended feedback that will be summarized qualitatively.

EmbracePlus, Care App and Aura safety: total number (%) of AEs and SAEsAfter 6 weeks of system usage

The second primary endpoint will be the total number (%) of AEs and SAEs related to the device use

Secondary Outcome Measures
NameTimeMethod
EmbracePlus, Care app and Aura reliability with different smartphonesSingle-point evaluation (baseline)

Evaluate the reliability of the system with different brands and models of smartphone by means of participants reported bugs and problems

Trial Locations

Locations (1)

Empatica Inc

🇺🇸

Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath